
Lupin Limited has informed the Exchange about press release dated 22-Sep-2022 titled Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w.
Filed with NSE ·

Lupin Limited has informed the Exchange about press release dated 22-Sep-2022 titled Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w.
6ix hasn’t read this filing yet.
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin